Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion
NYSEAMERICAN:YCBD

cbdMD Q3 2024 Earnings Report

cbdMD logo
$0.76 0.00 (0.00%)
Closing price 05/22/2026 04:10 PM Eastern
Extended Trading
$0.76 0.00 (-0.12%)
As of 05/22/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

cbdMD EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

cbdMD Revenue Results

Actual Revenue
$5.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

cbdMD Announcement Details

Quarter
Q3 2024
Date
8/14/2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:10PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

cbdMD's Q3 2024 Quarterly reportQuarterly report
(10-Q)

cbdMD Earnings Headlines

cbdMD Amends Lease, Adjusts Long-Term Facility Commitments
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cbdmd-amends-lease-adjusts-long-term-facility-commitments?utm_source=marketbeat.com&utm_medium=referral
cbdMD (YCBD) Stock Forecast & Price Target
May 20, 2026  |  investing.comhttps://www.investing.com/equities/level-brands-consensus-estimates
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
May 25 at 1:00 AM  |  Weiss Ratings (Ad)
cbdMD, Inc. (AMEX:YCBD) Q3 2026 Earnings Call Transcript
May 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cbdmd-inc-amexycbd-q3-2026-earnings-call-transcript-1763345/
cbdMD, Inc. (AMEX:YCBD) Q2 2026 Earnings Call Transcript
May 16, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cbdmd-inc-amexycbd-q2-2026-earnings-call-transcript-1763346/
cbdMD, Inc.: cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505879-cbdmd-inc-cbdmd-reports-19-year-over-year-and-12-sequential-revenue-growth-bluebird-acquisition-integration-and-medicare-bei-pathway-position-co-008.htm
See More cbdMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like cbdMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on cbdMD and other key companies, straight to your email.

About cbdMD

cbdMD (NYSEAMERICAN:YCBD) (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities. Third-party laboratory testing is conducted on every batch to verify potency and ensure products are free of THC or within federally approved limits. cbdMD markets both broad-spectrum and isolate-based formulations, targeting consumers seeking natural alternatives for stress relief, sleep support, and post-exercise recovery.

cbdMD’s distribution network spans e-commerce, major online marketplaces, and brick-and-mortar retailers across the United States, with expanding presence in select international markets. The company partners with pharmacies, specialty wellness stores, and veterinarians to broaden its retail footprint, while its direct-to-consumer website serves as a primary channel for product innovation feedback and subscription services.

Since its listing on the NYSE American exchange, cbdMD has pursued strategic product line extensions and marketing collaborations to drive brand awareness. The company emphasizes quality assurance, regulatory compliance, and ongoing research to support the evolving cannabinoid market and to meet consumer demand for trusted CBD solutions.

View cbdMD Profile
Earnings Tools